SHI, Y. .; LI, Y. .; CHEN, W. .; ZHANG, M. .; QIAN, D. .; LI, T. .; DAI, Y. .; LI, G. . Cost-effectiveness analysis of Sintilimab vs. Docetaxel as the second-line therapy of squamous non-small cell lung cancer in China. Health Decision, [S. l.], v. 2, n. S1, 2024. DOI: 10.54844/hd.2024.0007. Disponível em: https://www.hksmp.com/journals/hd/article/view/653. Acesso em: 2 may. 2025.